In the fed state, pharmacokinetic parameters for TAK-063 were comparable at equivalent doses between healthy Japanese subjects and subjects with stable schizophrenia.

TAK-063 was safe and generally well tolerated when administered once daily over a 7-day period to healthy Japanese subjects (up to 20 mg) and subjects with stable schizophrenia (up to 100 mg).

Pharmacokinetic/adverse event modeling suggests that single daily doses up to 30 mg TAK-063 may be suitable for further development in schizophrenia.